This report presents an overview of the samples of participants in four major large population cohorts, in Finland, Estonia, Norway and the Netherlands, who have developed pancreas cancer in the years after their enrolment (‘cases’) as well as a twice as high nr of samples of participants of the same biobanks, matched for age and gender, who have not developed this disease (‘controls’). Subsequently, in close consultation with the biobanks themselves, the status of the samples has been reviewed (actual availability, presence of informed consent, availability of phenotypic data, required local and national approvals procedures and completion thereof), followed by their shipment to the centralized address of THL (Helsinki, FI). In the next phase of the research, the samples will be subjected to metabolomics data generation at Brainshake Ltd (Helsinki, FI), after which all the data will be jointly analysed by the academic groups involved, with the aim of defining early metabolomic biomarkers for presymptomatic pancreas cancer.